MTOR and hepatocellular carcinoma: Currently, the results of an open-labeled, randomized, prospective multicenter trial comparing Sirolimus-containing vs. mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC are awaited (ClinicalTrial.gov identifier: NCT00355862) (Schnitzbauer et al., 2010).